Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Panopoulou, A. Easdale, S. Ethell, M. Nicholson, E. Potter, M. Giotas, A. Woods, H. Thornton, T. Pawlyn, C. Boyd, K.D. Kaiser, M.F. (2023). Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients. , Vol.7 (2), p. e831.  show abstract

Faustini, S.E. Hall, A. Brown, S. Roberts, S. Hill, H. Stamataki, Z. (PITCH) consortium,, Jenner, M.W. Owen, R.G. Pratt, G. Cook, G. Richter, A. Drayson, M.T. Kaiser, M.F. Heaney, J.L. (2023). Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. , Vol.201 (5), pp. 845-850.  show abstract

Panopoulou, A. Cairns, D.A. Holroyd, A. Nichols, I. Cray, N. Pawlyn, C. Cook, G. Drayson, M. Boyd, K. Davies, F.E. Jenner, M. Morgan, G.J. Owen, R. Houlston, R. Jackson, G. Kaiser, M.F. (2023). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. , , p. blood.2022018339.  show abstract

Jones, J.R. Cairns, D.A. Menzies, T. Pawlyn, C. Davies, F.E. Sigsworth, R. Brioli, A. Jenner, M.W. Kaiser, M.F. Olivier, C. Reed, M. Drayson, M.T. Owen, R.G. Boyd, K.D. Cook, G. Morgan, G.J. Jackson, G.H. (2023). Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. Eclinicalmedicine, Vol.62, pp. 102099-102099.

Kaiser, M.F. Hall, A. Walker, K. Sherborne, A. De Tute, R.M. Newnham, N. Roberts, S. Ingleson, E. Bowles, K. Garg, M. Lokare, A. Messiou, C. Houlston, R.S. Jackson, G. Cook, G. Pratt, G. Owen, R.G. Drayson, M.T. Brown, S.R. Jenner, M.W. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. , , p. JCO2202567.  show abstract

Keaveney, S. Dragan, A. Rata, M. Blackledge, M. Scurr, E. Winfield, J.M. Shur, J. Koh, D.-. Porta, N. Candito, A. King, A. Rennie, W. Gaba, S. Suresh, P. Malcolm, P. Davis, A. Nilak, A. Shah, A. Gandhi, S. Albrizio, M. Drury, A. Pratt, G. Cook, G. Roberts, S. Jenner, M. Brown, S. Kaiser, M. Messiou, C. (2023). Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study. , .  show abstract

Pawlyn, C. Cairns, D. Menzies, T. Jones, J. Jenner, M. Cook, G. Boyd, K. Drayson, M. Kaiser, M. Owen, R. Gregory, W. Morgan, G. Jackson, G. Davies, F. (2022). Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, Vol.Online ahead of print, pp. 0-?.  show abstract

de Tute, R.M. Pawlyn, C. Cairns, D.A. Davies, F.E. Menzies, T. Rawstron, A. Jones, J.R. Hockaday, A. Henderson, R. Cook, G. Drayson, M.T. Jenner, M.W. Kaiser, M.F. Gregory, W.M. Morgan, G.J. Jackson, G.H. Owen, R.G. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. , , p. JCO2102228.  show abstract

Auner, H.W. Brown, S.R. Walker, K. Kendall, J. Dawkins, B. Meads, D. Morgan, G.J. Kaiser, M.F. Cook, M. Roberts, S. Parrish, C. Cook, G. (2022). Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results. Blood cancer journal, Vol.12 (4), pp. 52-?.  show abstract

Usmani, S.Z. Nahi, H. Legiec, W. Grosicki, S. Vorobyev, V. Spicka, I. Hungria, V. Korenkova, S. Bahlis, N.J. Flogegard, M. Bladé, J. Moreau, P. Kaiser, M. Iida, S. Laubach, J. Magen, H. Cavo, M. Hulin, C. White, D. De Stefano, V. Lantz, K. O'Rourke, L. Heuck, C. Delioukina, M. Qin, X. Nnane, I. Qi, M. Mateos, M.-. (2022). Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma. , .  show abstract

Coulson, A.B. Royle, K.-. Pawlyn, C. Cairns, D.A. Hockaday, A. Bird, J. Bowcock, S. Kaiser, M. de Tute, R. Rabin, N. Boyd, K. Jones, J. Parrish, C. Gardner, H. Meads, D. Dawkins, B. Olivier, C. Henderson, R. Best, P. Owen, R. Jenner, M. Kishore, B. Drayson, M. Jackson, G. Cook, G. (2022). Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial. , Vol.12 (6), p. e056147.  show abstract

Caro, J. Cairns, D. Menzies, T. Boyle, E. Pawlyn, C. Cook, G. Kaiser, M. Walker, B.A. Owen, R. Jackson, G.H. Morgan, G.J. Heaney, J. Drayson, M.T. Davies, F.E. (2022). Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma. Clinical lymphoma myeloma and leukemia, Vol.22 (4), pp. e279-e284.

Satchwell, L. Wedlake, L. Greenlay, E. Li, X. Messiou, C. Glocker, B. Barwick, T. Barfoot, T. Doran, S. Leach, M.O. Koh, D.M. Kaiser, M. Winzeck, S. Qaiser, T. Aboagye, E. Rockall, A. (2022). Development of machine learning support for reading whole body diffusion-weighted MRI (WB-MRI) in myeloma for the detection and quantification of the extent of disease before and after treatment (MALIMAR): protocol for a cross-sectional diagnostic test accuracy study. , Vol.12 (10), p. e067140.  show abstract

Davies, F.E. Pawlyn, C. Usmani, S.Z. San-Miguel, J.F. Einsele, H. Boyle, E.M. Corre, J. Auclair, D. Cho, H.J. Lonial, S. Sonneveld, P. Stewart, A.K. Bergsagel, P.L. Kaiser, M.F. Weisel, K. Keats, J.J. Mikhael, J.R. Morgan, K.E. Ghobrial, I.M. Orlowski, R.Z. Landgren, C.O. Gay, F. Caers, J. Chng, W.J. Chari, A. Walker, B.A. Kumar, S.K. Costa, L.J. Anderson, K.C. Morgan, G.J. (2022). Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. , Vol.3 (4), pp. 273-284.  show abstract

Ajore, R. Niroula, A. Pertesi, M. Cafaro, C. Thodberg, M. Went, M. Bao, E.L. Duran-Lozano, L. Lopez de Lapuente Portilla, A. Olafsdottir, T. Ugidos-Damboriena, N. Magnusson, O. Samur, M. Lareau, C.A. Halldorsson, G.H. Thorleifsson, G. Norddahl, G.L. Gunnarsdottir, K. Försti, A. Goldschmidt, H. Hemminki, K. van Rhee, F. Kimber, S. Sperling, A.S. Kaiser, M. Anderson, K. Jonsdottir, I. Munshi, N. Rafnar, T. Waage, A. Weinhold, N. Thorsteinsdottir, U. Sankaran, V.G. Stefansson, K. Houlston, R. Nilsson, B. (2022). Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nature communications, Vol.13 (1), pp. 151-?.  show abstract

D'Agostino, M. Cairns, D.A. Lahuerta, J.J. Wester, R. Bertsch, U. Waage, A. Zamagni, E. Mateos, M.-. Dall'Olio, D. van de Donk, N.W. Jackson, G. Rocchi, S. Salwender, H. Bladé Creixenti, J. van der Holt, B. Castellani, G. Bonello, F. Capra, A. Mai, E.K. Dürig, J. Gay, F. Zweegman, S. Cavo, M. Kaiser, M.F. Goldschmidt, H. Hernández Rivas, J.M. Larocca, A. Cook, G. San-Miguel, J.F. Boccadoro, M. Sonneveld, P. (2022). Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. , , p. JCO2102614.  show abstract

Agbuduwe, C. Iqbal, G. Cairns, D. Menzies, T. Dunn, J. Gregory, W. Kaiser, M. Owen, R. Pawlyn, C. Child, J.A. Davies, F. Morgan, G.J. Jackson, G.H. Drayson, M.T. Basu, S. (2022). Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials. , Vol.6 (17), pp. 5113-5123.  show abstract

Jenner, M.W. Pawlyn, C. Davies, F.E. Menzies, T. Hockaday, A. Olivier, C. Jones, J.R. Karunanithi, K. Lindsay, J. Kishore, B. Cook, G. Drayson, M.T. Kaiser, M.F. Owen, R.G. Gregory, W. Cairns, D.A. Morgan, G.J. Jackson, G.H. UK National Cancer Research Institute (NCRI) Haemato-oncology Clinical Studies Group,, (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial. , .  show abstract

Went, M. Hoang, P.H. Law, P.J. Kaiser, M.F. Houlston, R.S. (2022). Exploiting gene dependency to inform drug development for multiple myeloma. , Vol.12 (1), p. 12696.  show abstract

Kendall, J. Hall, A. Roberts, S. Brown, S. Boyd, K. Auner, H.W. Garg, M. Kaiser, M. (2022). MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. , Vol.12 (10), p. e062504.  show abstract

Rata, M. Blackledge, M. Scurr, E. Winfield, J. Koh, D.-. Dragan, A. Candito, A. King, A. Rennie, W. Gaba, S. Suresh, P. Malcolm, P. Davis, A. Nilak, A. Shah, A. Gandhi, S. Albrizio, M. Drury, A. Roberts, S. Jenner, M. Brown, S. Kaiser, M. Messiou, C. (2022). Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. , Vol.13 (1), p. 123.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Allotey, D. Shafeek, S. Jenner, M.W. Cook, G. Russell, N.H. Kaiser, M.F. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. Clinical Studies Group, U.N. (2021). Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, .  show abstract

Jackson, G.H. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Wilson, J. Taylor, C. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Jenner, M.W. Cook, G. Russell, N.H. Drayson, M.T. Kaiser, M.F. Owen, R.G. Gregory, W.M. Davies, F.E. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group,, (2021). Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British journal of haematology, .  show abstract

Latifoltojar, A. Boyd, K. Riddell, A. Kaiser, M. Messiou, C. (2021). Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. Magnetic resonance imaging, Vol.75, pp. 60-64.  show abstract

Jackson, G.H. Pawlyn, C. Cairns, D.A. de Tute, R.M. Hockaday, A. Collett, C. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Rocci, A. Snowden, J.A. Jenner, M.W. Cook, G. Russell, N.H. Drayson, M.T. Gregory, W.M. Kaiser, M.F. Owen, R.G. Davies, F.E. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group,, (2021). Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. Plos medicine, Vol.18 (1), pp. e1003454-?.  show abstract

Barwick, T. Orton, M. Koh, D.M. Kaiser, M. Rockall, A. Tunariu, N. Blackledge, M. Messiou, C. (2021). Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. The british journal of radiology, Vol.94 (1120), pp. 20200682-?.  show abstract

Yong, K.L. Hinsley, S. Auner, H.W. Bygrave, C. Kaiser, M.F. Ramasamy, K. De Tute, R.M. Sherratt, D. Flanagan, L. Garg, M. Hawkins, S. Williams, C. Cavenagh, J. Rabin, N.K. Croft, J. Morgan, G. Davies, F. Owen, R.G. Brown, S.R. (2021). Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive). , Vol.106 (10), pp. 2694-2706.  show abstract

Weinhold, N. Salwender, H.J. Cairns, D.A. Raab, M.S. Waldron, G. Blau, I.W. Bertsch, U. Hielscher, T. Morgan, G.J. Jauch, A. Davies, F.E. Hänel, M. Cook, G. Scheid, C. Houlston, R. Goldschmidt, H. Jackson, G. Kaiser, M.F. (2021). Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica, .  show abstract

Musto, P. Engelhardt, M. Caers, J. Bolli, N. Kaiser, M. Van de Donk, N. Terpos, E. Broijl, A. De Larrea, C.F. Gay, F. Goldschmidt, H. Hajek, R. Vangsted, A.J. Zamagni, E. Zweegman, S. Cavo, M. Dimopoulos, M. Einsele, H. Ludwig, H. Barosi, G. Boccadoro, M. Mateos, M.-. Sonneveld, P. Miguel, J.S. (2021). 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr Jekyll and Mr Hyde. , Vol.106 (11), pp. 2799-2812.  show abstract

Messiou, C. Porta, N. Sharma, B. Levine, D. Koh, D.-. Boyd, K. Pawlyn, C. Riddell, A. Downey, K. Croft, J. Morgan, V. Stern, S. Cheung, B. Kyriakou, C. Kaczmarek, P. Winfield, J. Blackledge, M. Oyen, W.J. Kaiser, M.F. (2021). Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. , Vol.3 (5), p. e210048.  show abstract

Jones, J.R. Barber, A. Le Bihan, Y.-. Weinhold, N. Ashby, C. Walker, B.A. Wardell, C.P. Wang, H. Kaiser, M.F. Jackson, G.H. Davies, F.E. Chopra, R. Morgan, G.J. Pawlyn, C. (2021). Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia, Vol.35 (10), pp. 3017-3020.

Fernández de Larrea, C. Kyle, R. Rosiñol, L. Paiva, B. Engelhardt, M. Usmani, S. Caers, J. Gonsalves, W. Schjesvold, F. Merlini, G. Lentzch, S. Ocio, E. Garderet, L. Moreau, P. Sonneveld, P. Badros, A. Gahrton, G. Goldschmidt, H. Tuchman, S. Einsele, H. Durie, B. Wirk, B. Musto, P. Hayden, P. Kaiser, M. Miguel, J.S. Bladé, J. Rajkumar, S.V. Mateos, M.V. (2021). Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood cancer journal, Vol.11 (12), pp. 192-?.  show abstract

Brown, S. Pawlyn, C. Tillotson, A.-. Sherratt, D. Flanagan, L. Low, E. Morgan, G.J. Williams, C. Kaiser, M. Davies, F.E. Jenner, M.W. (2021). Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clinical lymphoma myeloma and leukemia, Vol.21 (3), pp. 154-161.e3.

Bird, S. Cairns, D. Menzies, T. Boyd, K. Davies, F. Cook, G. Drayson, M. Gregory, W. Jenner, M. Jones, J. Kaiser, M. Owen, R. Jackson, G. Morgan, G. Pawlyn, C. (2021). Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical lymphoma myeloma and leukemia, Vol.21 (10), pp. 667-675.

Terpos, E. Mikhael, J. Hajek, R. Chari, A. Zweegman, S. Lee, H.C. Mateos, M.-. Larocca, A. Ramasamy, K. Kaiser, M. Cook, G. Weisel, K.C. Costello, C.L. Elliott, J. Palumbo, A. Usmani, S.Z. (2021). Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood cancer journal, Vol.11 (2), pp. 40-?.  show abstract

Duran-Lozano, L. Thorleifsson, G. Lopez de Lapuente Portilla, A. Niroula, A. Went, M. Thodberg, M. Pertesi, M. Ajore, R. Cafaro, C. Olason, P.I. Stefansdottir, L. Bragi Walters, G. Halldorsson, G.H. Turesson, I. Kaiser, M.F. Weinhold, N. Abildgaard, N. Andersen, N.F. Mellqvist, U.-. Waage, A. Juul-Vangsted, A. Thorsteinsdottir, U. Hansson, M. Houlston, R. Rafnar, T. Stefansson, K. Nilsson, B. (2021). Germline variants at SOHLH2 influence multiple myeloma risk. Blood cancer journal, Vol.11 (4), pp. 76-?.  show abstract

Diamond, B. Yellapantula, V. Rustad, E.H. Maclachlan, K.H. Mayerhoefer, M. Kaiser, M. Morgan, G. Landgren, O. Maura, F. (2021). Positive selection as the unifying force for clonal evolution in multiple myeloma. Leukemia, .

Brown, S. Sherratt, D. Hinsley, S. Flanagan, L. Roberts, S. Walker, K. Hall, A. Pratt, G. Messiou, C. Jenner, M. Kaiser, M. Myeloma UK Early Phase Clinical Trial Network,, (2021). MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. Bmj open, Vol.11 (3), pp. e046225-?.  show abstract

Bird, S. Panopoulou, A. Shea, R.L. Tsui, M. Saso, R. Sud, A. West, S. Smith, K. Barwood, J. Kaczmarek, E. Panlaqui, C. Kaiser, M. Stern, S. Pawlyn, C. Boyd, K. (2021). Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. The lancet. haematology, .

Verkleij, C.P. Broekmans, M.E. van Duin, M. Frerichs, K.A. Kuiper, R. de Jonge, A.V. Kaiser, M. Morgan, G. Axel, A. Boominathan, R. Sendecki, J. Wong, A. Verona, R.I. Sonneveld, P. Zweegman, S. Adams, H.C. Mutis, T. van de Donk, N.W. (2021). Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood advances, Vol.5 (8), pp. 2196-2215.  show abstract

Saavedra-García, P. Roman-Trufero, M. Al-Sadah, H.A. Blighe, K. López-Jiménez, E. Christoforou, M. Penfold, L. Capece, D. Xiong, X. Miao, Y. Parzych, K. Caputo, V.S. Siskos, A.P. Encheva, V. Liu, Z. Thiel, D. Kaiser, M.F. Piazza, P. Chaidos, A. Karadimitris, A. Franzoso, G. Snijders, A.P. Keun, H.C. Oyarzún, D.A. Barahona, M. Auner, H.W. (2021). Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs. Proceedings of the national academy of sciences of the united states of america, Vol.118 (17).  show abstract

Lai, A.Y. Riddell, A. Barwick, T. Boyd, K. Rockall, A. Kaiser, M. Koh, D.-. Saffar, H. Yusuf, S. Messiou, C. (2020). Interobserver agreement of whole-body magnetic resonance imaging is superior to whole-body computed tomography for assessing disease burden in patients with multiple myeloma. European radiology, Vol.30 (1), pp. 320-327.  show abstract

Pawlyn, C. Cairns, D. Kaiser, M. Striha, A. Jones, J. Shah, V. Jenner, M. Drayson, M. Owen, R. Gregory, W. Cook, G. Morgan, G. Jackson, G. Davies, F. (2020). The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, Vol.34 (2), pp. 604-612.  show abstract

Hoang, P.H. Cornish, A.J. Chubb, D. Jackson, G. Kaiser, M. Houlston, R.S. (2020). Impact of mitochondrial DNA mutations in multiple myeloma. Blood cancer journal, Vol.10 (5), pp. 46-?.

Menezes, K. Atanesyan, L. Sherborne, A.L. Steenkamer, M. Clemens, I. Savola, S. Kaiser, M.F. (2020). High-Throughput Molecular Cancer Cell Line Characterization Using Digital Multiplex Ligation-Dependent Probe Amplification for Improved Standardization of in Vitro Research. The journal of molecular diagnostics : jmd, Vol.22 (9), pp. 1179-1188.  show abstract

Kaiser, M. Beksaç, M. Gulbrandsen, N. Schjesvold, F. Hájek, R. Moreau, P. de Arriba de la Fuente, F. Mateos, M.-. West, S. Spencer, A. Rajkumar, S.V. Suryanarayan, K. Czorniak, M. Li, C. Teng, Z. Labotka, R. Dimopoulos, M.A. (2020). Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Annals of hematology, Vol.99 (8), pp. 1793-1804.  show abstract

Croft, J. Ellis, S. Sherborne, A.L. Sharp, K. Price, A. Jenner, M.W. Drayson, M.T. Owen, R.G. Chown, S. Lindsay, J. Karunanithi, K. Hunter, H. Gregory, W.M. Davies, F.E. Morgan, G.J. Cook, G. Atanesyan, L. Savola, S. Cairns, D.A. Jackson, G. Houlston, R.S. Kaiser, M.F. (2020). Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, .  show abstract

Guo, C. Chénard-Poirier, M. Roda, D. de Miguel, M. Harris, S.J. Candilejo, I.M. Sriskandarajah, P. Xu, W. Scaranti, M. Constantinidou, A. King, J. Parmar, M. Turner, A.J. Carreira, S. Riisnaes, R. Finneran, L. Hall, E. Ishikawa, Y. Nakai, K. Tunariu, N. Basu, B. Kaiser, M. Lopez, J.S. Minchom, A. de Bono, J.S. Banerji, U. (2020). Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. The lancet oncology, .  show abstract

Kühnl, A. Peckitt, C. Patel, B. Ardeshna, K.M. Macheta, M.P. Radford, J. Johnson, R. Paneesha, S. Barton, S. Chau, I. Begum, R. Valeri, N. Wotherspoon, A. Du, Y. Zerizer, I. Cunningham, D. (2020). R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial. Annals of hematology, Vol.99 (1), pp. 105-112.

Luo, M.M. Usmani, S.Z. Mateos, M.-. Nahi, H. Chari, A. San-Miguel, J. Touzeau, C. Suzuki, K. Kaiser, M. Carson, R. Heuck, C. Qi, M. Zhou, H. Sun, Y.-. Parasrampuria, D.A. (2020). Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. Journal of clinical pharmacology, .  show abstract

Mateos, M.-. Nahi, H. Legiec, W. Grosicki, S. Vorobyev, V. Spicka, I. Hungria, V. Korenkova, S. Bahlis, N. Flogegard, M. Bladé, J. Moreau, P. Kaiser, M. Iida, S. Laubach, J. Magen, H. Cavo, M. Hulin, C. White, D. De Stefano, V. Clemens, P.L. Masterson, T. Lantz, K. O'Rourke, L. Heuck, C. Qin, X. Parasrampuria, D.A. Yuan, Z. Xu, S. Qi, M. Usmani, S.Z. (2020). Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet haematol, Vol.7 (5), pp. e370-e380.  show abstract

Kaiser, M.F. Boyd, K. Koh, D. Rata, M. Blackledge, M. Messiou, C. (2020). Improving real‐world myeloma patient access to whole body MRI through “open‐access” knowledge sharing: The UK experience. Ejhaem, Vol.1 (1), pp. 361-363.

Bygrave, C. Pawlyn, C. Davies, F. Craig, Z. Cairns, D. Hockaday, A. Jenner, M. Cook, G. Drayson, M. Owen, R. Gregory, W. Morgan, G. Jackson, G. Kaiser, M. (2020). Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. British journal of haematology, .  show abstract

Shah, V. Sherborne, A.L. Johnson, D.C. Ellis, S. Price, A. Chowdhury, F. Kendall, J. Jenner, M.W. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. Davies, F.E. Cook, G. Cairns, D.A. Houlston, R.S. Jackson, G. Kaiser, M.F. on behalf of NCRI Haematology Clinical Studies Group,, (2020). Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, Vol.34 (11), pp. 3091-3096.

Croft, J. Riddell, A. Koh, D.-. Downey, K. Blackledge, M. Usher, M. Boyd, K. Kaiser, M. Messiou, C. (2020). Inter-observer agreement of baseline whole body MRI in multiple myeloma. Cancer imaging : the official publication of the international cancer imaging society, Vol.20 (1), pp. 48-?.  show abstract

Hoang, P.H. Cornish, A.J. Sherborne, A.L. Chubb, D. Kimber, S. Jackson, G. Morgan, G.J. Cook, G. Kinnersley, B. Kaiser, M. Houlston, R.S. (2020). An enhanced genetic model of relapsed IGH-translocated multiple myeloma evolutionary dynamics. Blood cancer journal, Vol.10 (10), pp. 101-?.  show abstract

Went, M. Cornish, A.J. Law, P.J. Kinnersley, B. van Duin, M. Weinhold, N. Försti, A. Hansson, M. Sonneveld, P. Goldschmidt, H. Morgan, G.J. Hemminki, K. Nilsson, B. Kaiser, M. Houlston, R.S. (2020). Search for multiple myeloma risk factors using Mendelian randomization. Blood advances, Vol.4 (10), pp. 2172-2179.  show abstract

Bradbury, C.A. Craig, Z. Cook, G. Pawlyn, C. Cairns, D.A. Hockaday, A. Paterson, A. Jenner, M.W. Jones, J.R. Drayson, M.T. Owen, R.G. Kaiser, M.F. Gregory, W.M. Davies, F.E. Child, J.A. Morgan, G.J. Jackson, G.H. (2020). Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, Vol.136 (9), pp. 1091-1104.  show abstract

Sriskandarajah, P. De Haven Brandon, A. MacLeod, K. Carragher, N.O. Kirkin, V. Kaiser, M. Whittaker, S.R. (2020). Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma. Bmc cancer, Vol.20 (1), pp. 269-?.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Hockaday, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Jenner, M.W. Cook, G. Russell, N.H. Kaiser, M.F. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group,, (2019). Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The lancet. oncology, Vol.20 (1), pp. 57-73.  show abstract

Dimopoulos, M.A. Gay, F. Schjesvold, F. Beksac, M. Hajek, R. Weisel, K.C. Goldschmidt, H. Maisnar, V. Moreau, P. Min, C.K. Pluta, A. Chng, W.-. Kaiser, M. Zweegman, S. Mateos, M.-. Spencer, A. Iida, S. Morgan, G. Suryanarayan, K. Teng, Z. Skacel, T. Palumbo, A. Dash, A.B. Gupta, N. Labotka, R. Rajkumar, S.V. Bar, D. Basso, A. Fantl, D. He, S. Horvath, N. Lee, C. Rowlings, P. Taylor, K. Spencer, A. Cochrane, T. Kwok, F. Ramanathan, S. Agis, H. Zojer, N. Kentos, A. Offner, F. Van Droogenbroeck, J. Wu, K.L. Maiolino, A. Martinez, G. Zanella, K. Capra, M. Araújo, S. Gregora, E. Hajek, R. Maisnar, V. Pour, L. Scudla, V. Spicka, I. Abildgaard, N. Andersen, N. Jensen, B.A. Helleberg, C. Plesner, T. Salomo, M. Svirskaite, A. Delarue, R. Moreau, P. Blau, I. Goldschmidt, H. Schieferdecker, A. Teleanu, V. Munder, M. Röllig, C. Salwender, H.-. Fuhrmann, S. Weisel, K. Duerig, J. Zeis, M. Klein, S. Reimer, P. Schmidt, C. Scheid, C. Mayer, K. Hoffmann, M. Sosada, M. Dimopoulos, A. Delimpasi, S. Kyrtsonis, M.-. Anagnostopoulos, A. Nagy, Z. Illés, Á. Egyed, M. Borbényi, Z. Mikala, G. Dally, N. Horowitz, N. Gutwein, O. Nemets, A. Vaxman, I. Shvetz, O. Trestman, S. Ruchlemer, R. Nagler, A. Tadmor, T. Rouvio, O. Preis, M. Gay, F. Cavo, M. De Rosa, L. Musto, P. Cafro, A. Tosi, P. Offidani, M. Corso, A. Rossi, G. Liberati, A.M. Bosi, A. Suzuki, K. Iida, S. Nakaseko, C. Ishikawa, T. Matsumoto, M. Nagai, H. Sunami, K. Chou, T. Akashi, K. Takezako, N. Hagiwara, S. Eom, H.S. Jo, D.-. Kim, J.S. Lee, J.H. Min, C.K. Yoon, S.S. Yoon, D.H. Kim, K. Zweegman, S. Levin, M.-. Vellenga, E. Minnema, M. Schjesvold, F. Waage, A. Haukås, E. Grosicki, S. Pluta, A. Robak, T. Marques, H. Bergantim, R. Campilho, F. Chng, W.J. Goh, Y.T. McDonald, A. Rapoport, B. Álvarez Rivas, M.A. De Arriba de La Fuente, F. González Montes, Y. Martin Sanchez, J. Mateos, M.V. Oriol Rocafiguera, A. Rosinol, L. San Miguel, J. Pérez de Oteyza, J. Encinas, C. Alegre-Amor, A. López-Guía, A. Axelsson, P. Carlson, K. Stromberg, O. Hansson, M. Hveding Blimark, C. Mueller, R. Chen, C.-. Liu, T.-. Huang, S.-. Wang, P.-. Na Nakorn, T. Prayongratana, K. Beksac, M. Unal, A. Goker, H. Sonmez, M. Korenkova, S. Chaidos, A. Oakervee, H. Sati, H. Benjamin, R. Wechalekar, A. Garg, M. Kaiser, M. Ramasamy, K. Cook, G. Chantry, A. Jenner, M. Buadi, F. Berryman, R. Janakiram, M. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. The lancet, Vol.393 (10168), pp. 253-264.

Ahmed, N. Sriskandarajah, P. Burd, C. Riddell, A. Boyd, K. Kaiser, M. Messiou, C. (2019). Detection of avascular necrosis on routine diffusion-weighted whole body MRI in patients with multiple myeloma. The british journal of radiology, Vol.92 (1097), pp. 20180822-?.  show abstract

Cook, G. Royle, K.-. Pawlyn, C. Hockaday, A. Shah, V. Kaiser, M.F. Brown, S.R. Gregory, W.M. Child, J.A. Davies, F.E. Morgan, G.J. Cairns, D.A. Jackson, G.H. (2019). A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. The lancet. haematology, Vol.6 (3), pp. e154-e166.  show abstract

Went, M. Sud, A. Li, N. Johnson, D.C. Mitchell, J.S. Kaiser, M. Houlston, R.S. (2019). Regions of homozygosity as risk factors for multiple myeloma. Annals of human genetics, Vol.83 (4), pp. 231-238.  show abstract

Messiou, C. Hillengass, J. Delorme, S. Lecouvet, F.E. Moulopoulos, L.A. Collins, D.J. Blackledge, M.D. Abildgaard, N. Østergaard, B. Schlemmer, H.-. Landgren, O. Asmussen, J.T. Kaiser, M.F. Padhani, A. (2019). Guidelines for Acquisition, Interpretation, and Reporting of Whole-Body MRI in Myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology, Vol.291 (1), pp. 5-13.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Wilson, J.N. Jenner, M.W. Cook, G. Kaiser, M.F. Drayson, M.T. Owen, R.G. Russell, N.H. Gregory, W.M. Morgan, G.J. UK NCRI Haematological Oncology Clinical Studies Group,, (2019). Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The lancet. haematology, Vol.6 (12), pp. e616-e629.  show abstract

Hoang, P.H. Cornish, A.J. Dobbins, S.E. Kaiser, M. Houlston, R.S. (2019). Mutational processes contributing to the development of multiple myeloma. Blood cancer journal, Vol.9 (8), pp. 60-?.  show abstract

Went, M. Kinnersley, B. Sud, A. Johnson, D.C. Weinhold, N. Försti, A. van Duin, M. Orlando, G. Mitchell, J.S. Kuiper, R. Walker, B.A. Gregory, W.M. Hoffmann, P. Jackson, G.H. Nöthen, M.M. da Silva Filho, M.I. Thomsen, H. Broyl, A. Davies, F.E. Thorsteinsdottir, U. Hansson, M. Kaiser, M. Sonneveld, P. Goldschmidt, H. Stefansson, K. Hemminki, K. Nilsson, B. Morgan, G.J. Houlston, R.S. (2019). Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes. Human genomics, Vol.13 (1), pp. 37-?.  show abstract

Parzych, K. Saavedra-García, P. Valbuena, G.N. Al-Sadah, H.A. Robinson, M.E. Penfold, L. Kuzeva, D.M. Ruiz-Tellez, A. Loaiza, S. Holzmann, V. Caputo, V. Johnson, D.C. Kaiser, M.F. Karadimitris, A. Lam, E.W. Chevet, E. Feldhahn, N. Keun, H.C. Auner, H.W. (2019). The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation. Oncogene, Vol.38 (17), pp. 3216-3231.  show abstract

Jones, J.R. Weinhold, N. Ashby, C. Walker, B.A. Wardell, C. Pawlyn, C. Rasche, L. Melchor, L. Cairns, D.A. Gregory, W.M. Johnson, D. Begum, D.B. Ellis, S. Sherborne, A.L. Cook, G. Kaiser, M.F. Drayson, M.T. Owen, R.G. Jackson, G.H. Davies, F.E. Greaves, M. Morgan, G.J. NCRI Haemato-Oncology CSG,, (2019). Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, Vol.104 (7), pp. 1440-1450.  show abstract

Shah, V. Sherborne, A.L. Walker, B.A. Johnson, D.C. Boyle, E.M. Ellis, S. Begum, D.B. Proszek, P.Z. Jones, J.R. Pawlyn, C. Savola, S. Jenner, M.W. Drayson, M.T. Owen, R.G. Houlston, R.S. Cairns, D.A. Gregory, W.M. Cook, G. Davies, F.E. Jackson, G.H. Morgan, G.J. Kaiser, M.F. (2018). Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia, Vol.32 (1), pp. 102-110.  show abstract

Winfield, J.M. Poillucci, G. Blackledge, M.D. Collins, D.J. Shah, V. Tunariu, N. Kaiser, M.F. Messiou, C. (2018). Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI. European radiology, Vol.28 (4), pp. 1687-1691.  show abstract

Heaney, J.L. Campbell, J.P. Iqbal, G. Cairns, D. Richter, A. Child, J.A. Gregory, W. Jackson, G. Kaiser, M. Owen, R. Davies, F. Morgan, G. Dunn, J. Drayson, M.T. (2018). Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia, Vol.32 (8), pp. 1727-1738.  show abstract

Shah, V. Johnson, D.C. Sherborne, A.L. Ellis, S. Aldridge, F.M. Howard-Reeves, J. Begum, F. Price, A. Kendall, J. Chiecchio, L. Savola, S. Jenner, M.W. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. Davies, F.E. Houlston, R.S. Cook, G. Cairns, D.A. Jackson, G. Kaiser, M.F. National Cancer Research Institute Haematology Clinical Studies Group,, (2018). Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, Vol.132 (23), pp. 2465-2469.  show abstract

Hoang, P.H. Dobbins, S.E. Cornish, A.J. Chubb, D. Law, P.J. Kaiser, M. Houlston, R.S. (2018). Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia, Vol.32 (11), pp. 2459-2470.  show abstract

Messiou, C. Kaiser, M. (2018). Whole-Body Imaging in Multiple Myeloma. Magnetic resonance imaging clinics of north america, Vol.26 (4), pp. 509-525.

Raje, N. Chau, I. Hyman, D.M. Ribrag, V. Blay, J.-. Tabernero, J. Elez, E. Wolf, J. Yee, A.J. Kaiser, M. Landau, H. Michot, J.-. Hollebecque, A. Veronese, L. Makrutzki, M. Pitcher, B. Puzanov, I. Baselga, J. (2018). Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. Jco precision oncology, (2), pp. 1-9.

Went, M. Sud, A. Försti, A. Halvarsson, B.-. Weinhold, N. Kimber, S. van Duin, M. Thorleifsson, G. Holroyd, A. Johnson, D.C. Li, N. Orlando, G. Law, P.J. Ali, M. Chen, B. Mitchell, J.S. Gudbjartsson, D.F. Kuiper, R. Stephens, O.W. Bertsch, U. Broderick, P. Campo, C. Bandapalli, O.R. Einsele, H. Gregory, W.A. Gullberg, U. Hillengass, J. Hoffmann, P. Jackson, G.H. Jöckel, K.-. Johnsson, E. Kristinsson, S.Y. Mellqvist, U.-. Nahi, H. Easton, D. Pharoah, P. Dunning, A. Peto, J. Canzian, F. Swerdlow, A. Eeles, R.A. Kote-Jarai, Z. Muir, K. Pashayan, N. Nickel, J. Nöthen, M.M. Rafnar, T. Ross, F.M. da Silva Filho, M.I. Thomsen, H. Turesson, I. Vangsted, A. Andersen, N.F. Waage, A. Walker, B.A. Wihlborg, A.-. Broyl, A. Davies, F.E. Thorsteinsdottir, U. Langer, C. Hansson, M. Goldschmidt, H. Kaiser, M. Sonneveld, P. Stefansson, K. Morgan, G.J. Hemminki, K. Nilsson, B. Houlston, R.S. PRACTICAL consortium, (2018). Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nature communications, Vol.9 (1), pp. 3707-?.  show abstract

Went, M. Sud, A. Speedy, H. Sunter, N.J. Försti, A. Law, P.J. Johnson, D.C. Mirabella, F. Holroyd, A. Li, N. Orlando, G. Weinhold, N. van Duin, M. Chen, B. Mitchell, J.S. Mansouri, L. Juliusson, G. Smedby, K.E. Jayne, S. Majid, A. Dearden, C. Allsup, D.J. Bailey, J.R. Pratt, G. Pepper, C. Fegan, C. Rosenquist, R. Kuiper, R. Stephens, O.W. Bertsch, U. Broderick, P. Einsele, H. Gregory, W.M. Hillengass, J. Hoffmann, P. Jackson, G.H. Jöckel, K.-. Nickel, J. Nöthen, M.M. da Silva Filho, M.I. Thomsen, H. Walker, B.A. Broyl, A. Davies, F.E. Hansson, M. Goldschmidt, H. Dyer, M.J. Kaiser, M. Sonneveld, P. Morgan, G.J. Hemminki, K. Nilsson, B. Catovsky, D. Allan, J.M. Houlston, R.S. (2018). Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology. Blood cancer journal, Vol.9 (1), pp. 1-?.  show abstract

Bødker, J.S. Brøndum, R.F. Schmitz, A. Schönherz, A.A. Jespersen, D.S. Sønderkær, M. Vesteghem, C. Due, H. Nørgaard, C.H. Perez-Andres, M. Samur, M.K. Davies, F. Walker, B. Pawlyn, C. Kaiser, M. Johnson, D. Bertsch, U. Broyl, A. van Duin, M. Shah, R. Johansen, P. Nørgaard, M.A. Samworth, R.J. Sonneveld, P. Goldschmidt, H. Morgan, G.J. Orfao, A. Munshi, N. Johnson, H.E. El-Galaly, T. Dybkær, K. Bøgsted, M. (2018). A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood advances, Vol.2 (18), pp. 2400-2411.  show abstract

Boyle, E.M. Ashby, C. Wardell, C.P. Rowczenio, D. Sachchithanantham, S. Wang, Y. Johnson, S.K. Bauer, M.A. Weinhold, N. Kaiser, M.F. Johnson, D.C. Jones, J.R. Pawlyn, C. Proszek, P. Schinke, C. Facon, T. Dumontet, C. Davies, F.E. Morgan, G.J. Walker, B.A. Wechalekar, A.D. (2018). The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, Vol.132 (26), pp. 2775-2777.

Moreau, P. Dimopoulos, M.A. Richardson, P.G. Siegel, D.S. Cavo, M. Corradini, P. Weisel, K. Delforge, M. O'Gorman, P. Song, K. Chen, C. Bahlis, N. Oriol, A. Hansson, M. Kaiser, M. Anttila, P. Raymakers, R. Joao, C. Cook, G. Sternas, L. Biyukov, T. Slaughter, A. Hong, K. Herring, J. Yu, X. Zaki, M. San-Miguel, J. (2017). Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. European journal of haematology, Vol.99 (3), pp. 199-206.  show abstract

Campbell, J.P. Heaney, J.L. Pandya, S. Afzal, Z. Kaiser, M. Owen, R. Child, J.A. Gregory, W. Morgan, G.J. Jackson, G.H. Bunce, C.M. Drayson, M.T. (2017). Active multiple myeloma suppresses and typically eliminates coexisting MGUS. British journal of cancer, Vol.117 (6), pp. 835-839.  show abstract

Johnson, D.C. Lenive, O. Mitchell, J. Jackson, G. Owen, R. Drayson, M. Cook, G. Jones, J.R. Pawlyn, C. Davies, F.E. Walker, B.A. Wardell, C. Gregory, W.M. Cairns, D. Morgan, G.J. Houlston, R.S. Kaiser, M.F. (2017). Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, Vol.130 (14), pp. 1639-1643.  show abstract

Shah, V. Boyd, K.D. Houlston, R.S. Kaiser, M.F. (2017). Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. Bmc cancer, Vol.17 (1), pp. 718-?.  show abstract

Li, N. Johnson, D.C. Weinhold, N. Kimber, S. Dobbins, S.E. Mitchell, J.S. Kinnersley, B. Sud, A. Law, P.J. Orlando, G. Scales, M. Wardell, C.P. Försti, A. Hoang, P.H. Went, M. Holroyd, A. Hariri, F. Pastinen, T. Meissner, T. Goldschmidt, H. Hemminki, K. Morgan, G.J. Kaiser, M. Houlston, R.S. (2017). Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. Cell reports, Vol.20 (11), pp. 2556-2564.  show abstract

Campbell, J.P. Heaney, J.L. Pandya, S. Afzal, Z. Kaiser, M. Owen, R. Child, J.A. Cairns, D.A. Gregory, W. Morgan, G.J. Jackson, G.H. Bunce, C.M. Drayson, M.T. (2017). Response comparison of multiple myeloma and monoclonal gammopathy of undetermined significance to the same anti-myeloma therapy: a retrospective cohort study. The lancet haematology, Vol.4 (12), pp. e584-e594.

Went, M. Sud, A. Law, P.J. Johnson, D.C. Weinhold, N. Försti, A. van Duin, M. Mitchell, J.S. Chen, B. Kuiper, R. Stephens, O.W. Bertsch, U. Campo, C. Einsele, H. Gregory, W.M. Henrion, M. Hillengass, J. Hoffmann, P. Jackson, G.H. Lenive, O. Nickel, J. Nöthen, M.M. da Silva Filho, M.I. Thomsen, H. Walker, B.A. Broyl, A. Davies, F.E. Langer, C. Hansson, M. Kaiser, M. Sonneveld, P. Goldschmidt, H. Hemminki, K. Nilsson, B. Morgan, G.J. Houlston, R.S. (2017). Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach. Blood cancer journal, Vol.7 (6), pp. e573-?.

Law, P.J. Sud, A. Mitchell, J.S. Henrion, M. Orlando, G. Lenive, O. Broderick, P. Speedy, H.E. Johnson, D.C. Kaiser, M. Weinhold, N. Cooke, R. Sunter, N.J. Jackson, G.H. Summerfield, G. Harris, R.J. Pettitt, A.R. Allsup, D.J. Carmichael, J. Bailey, J.R. Pratt, G. Rahman, T. Pepper, C. Fegan, C. von Strandmann, E.P. Engert, A. Försti, A. Chen, B. Filho, M.I. Thomsen, H. Hoffmann, P. Noethen, M.M. Eisele, L. Jöckel, K.-. Allan, J.M. Swerdlow, A.J. Goldschmidt, H. Catovsky, D. Morgan, G.J. Hemminki, K. Houlston, R.S. (2017). Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci. Scientific reports, Vol.7, pp. 41071-?.  show abstract

Pawlyn, C. Bright, M.D. Buros, A.F. Stein, C.K. Walters, Z. Aronson, L.I. Mirabella, F. Jones, J.R. Kaiser, M.F. Walker, B.A. Jackson, G.H. Clarke, P.A. Bergsagel, P.L. Workman, P. Chesi, M. Morgan, G.J. Davies, F.E. (2017). Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood cancer journal, Vol.7 (3), pp. e549-?.  show abstract

Mitchell, J.S. Li, N. Weinhold, N. Försti, A. Ali, M. van Duin, M. Thorleifsson, G. Johnson, D.C. Chen, B. Halvarsson, B.-. Gudbjartsson, D.F. Kuiper, R. Stephens, O.W. Bertsch, U. Broderick, P. Campo, C. Einsele, H. Gregory, W.A. Gullberg, U. Henrion, M. Hillengass, J. Hoffmann, P. Jackson, G.H. Johnsson, E. Jöud, M. Kristinsson, S.Y. Lenhoff, S. Lenive, O. Mellqvist, U.-. Migliorini, G. Nahi, H. Nelander, S. Nickel, J. Nöthen, M.M. Rafnar, T. Ross, F.M. da Silva Filho, M.I. Swaminathan, B. Thomsen, H. Turesson, I. Vangsted, A. Vogel, U. Waage, A. Walker, B.A. Wihlborg, A.-. Broyl, A. Davies, F.E. Thorsteinsdottir, U. Langer, C. Hansson, M. Kaiser, M. Sonneveld, P. Stefansson, K. Morgan, G.J. Goldschmidt, H. Hemminki, K. Nilsson, B. Houlston, R.S. (2016). Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nature communications, Vol.7, pp. 12050-?.  show abstract

Pawlyn, C. Kaiser, M.F. Heuck, C. Melchor, L. Wardell, C.P. Murison, A. Chavan, S.S. Johnson, D.C. Begum, D.B. Dahir, N.M. Proszek, P.Z. Cairns, D.A. Boyle, E.M. Jones, J.R. Cook, G. Drayson, M.T. Owen, R.G. Gregory, W.M. Jackson, G.H. Barlogie, B. Davies, F.E. Walker, B.A. Morgan, G.J. (2016). The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clinical cancer research : an official journal of the american association for cancer research, Vol.22 (23), pp. 5783-5794.  show abstract

Wale, A. Pawlyn, C. Kaiser, M. Messiou, C. (2016). Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma. Haematologica, Vol.101 (4), pp. e142-e144.

Pawlyn, C. Fowkes, L. Otero, S. Jones, J.R. Boyd, K.D. Davies, F.E. Morgan, G.J. Collins, D.J. Sharma, B. Riddell, A. Kaiser, M.F. Messiou, C. (2016). Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?. Leukemia, Vol.30 (6), pp. 1446-1448.

Jones, J.R. Cairns, D.A. Gregory, W.M. Collett, C. Pawlyn, C. Sigsworth, R. Striha, A. Henderson, R. Kaiser, M.F. Jenner, M. Cook, G. Russell, N.H. Williams, C. Pratt, G. Kishore, B. Lindsay, J. Drayson, M.T. Davies, F.E. Boyd, K.D. Owen, R.G. Jackson, G.H. Morgan, G.J. (2016). Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood cancer journal, Vol.6 (12), pp. e506-?.  show abstract

Brown, S. Hinsley, S. Ballesteros, M. Bourne, S. McGarry, P. Sherratt, D. Flanagan, L. Gregory, W. Cavenagh, J. Owen, R. Williams, C. Kaiser, M. Low, E. Yong, K. (2016). The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma. Bmc hematology, Vol.16 (1).

Li, N. Johnson, D.C. Weinhold, N. Studd, J.B. Orlando, G. Mirabella, F. Mitchell, J.S. Meissner, T. Kaiser, M. Goldschmidt, H. Hemminki, K. Morgan, G.J. Houlston, R.S. (2016). Multiple myeloma risk variant at 7p15 3 creates an IRF4-binding site and interferes with CDCA7L expression. Nature communications, Vol.7, pp. 13656-?.  show abstract

Dimopoulos, M.A. Palumbo, A. Corradini, P. Cavo, M. Delforge, M. Di Raimondo, F. Weisel, K.C. Oriol, A. Hansson, M. Vacca, A. Blanchard, M.J. Goldschmidt, H. Doyen, C. Kaiser, M. Petrini, M. Anttila, P. Cafro, A.M. Raymakers, R. San-Miguel, J. de Arriba, F. Knop, S. Röllig, C. Ocio, E.M. Morgan, G. Miller, N. Simcock, M. Peluso, T. Herring, J. Sternas, L. Zaki, M.H. Moreau, P. (2016). Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood, Vol.128 (4), pp. 497-503.  show abstract

Johnson, D.C. Weinhold, N. Mitchell, J.S. Chen, B. Kaiser, M. Hillengass, J. Bertsch, U. Gregory, W.A. Cairns, D. Jackson, G.H. others, (2016). Genome-wide association study identifies variation at 6q25 1 associated with survival in multiple myeloma. Nature communications, Vol.7.

Johnson, D.C. Weinhold, N. Mitchell, J. Chen, B. Stephens, O.W. Försti, A. Nickel, J. Kaiser, M. Gregory, W.A. Cairns, D. others, (2016). Genetic factors influencing the risk of multiple myeloma bone disease. Leukemia, Vol.30, pp. 883-888.

Boyle, E.M. Proszek, P.Z. Kaiser, M.F. Begum, D. Dahir, N. Savola, S. Wardell, C.P. Leleu, X. Ross, F.M. Chiecchio, L. Cook, G. Drayson, M.T. Owen, R.G. Ashcroft, J.M. Jackson, G.H. Child, J.A. Davies, F.E. Walker, B.A. Morgan, G.J. (2015). A Molecular Diagnostic Approach Able to Detect the Recurrent Genetic Prognostic Factors Typical of Presenting Myeloma. Genes chromosomes & cancer, Vol.54 (2), pp. 91-98.

Raje, N. Chau, I. Hyman, D.M. Ribrag, V. Blay, J.-. Tabernero, J. Elez, E. Wolf, J. Yee, A.J. Kaiser, M. Landau, H. Michot, J.-. Hollebecque, A. Veronese, L. Makrutzki, M. Pitcher, B. Puzanov, I. Baselga, J. (2015). Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF V600 Mutations: A Cohort of the Histology-Independent VE-BASKET Study. Jco precision oncology, Vol.2.

Kühnl, A. Valk, P.J. Sanders, M.A. Ivey, A. Hills, R.K. Mills, K.I. Gale, R.E. Kaiser, M.F. Dillon, R. Joannides, M. Gilkes, A. Haferlach, T. Schnittger, S. Duprez, E. Linch, D.C. Delwel, R. Löwenberg, B. Baldus, C.D. Solomon, E. Burnett, A.K. Grimwade, D. (2015). Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia. Blood, Vol.125 (19), pp. 2985-2994.  show abstract

Messiou, C. Kaiser, M. (2015). Whole body diffusion weighted MRI – a new view of myeloma. British journal of haematology, Vol.171 (1), pp. 29-37.  show abstract

Pawlyn, C. Melchor, L. Murison, A. Wardell, C.P. Brioli, A. Boyle, E.M. Kaiser, M.F. Walker, B.A. Begum, D.B. Dahir, N.B. Proszek, P. Gregory, W.M. Drayson, M.T. Jackson, G.H. Ross, F.M. Davies, F.E. Morgan, G.J. (2015). Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood, Vol.125 (5), pp. 831-840.  show abstract

Walker, B.A. Wardell, C.P. Murison, A. Boyle, E.M. Dahir, N.M. Proszek, P.Z. Melchor, L. Pawlyn, C. Kaiser, M.F. Johnson, D.C. others, (2015). APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature communications, Vol.6.

Wu, P. Walker, B.A. Broyl, A. Kaiser, M. Johnson, D.C. Kuiper, R. van Duin, M. Gregory, W.M. Davies, F.E. Brewer, D. others, (2015). A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leukemia & lymphoma, Vol.56, pp. 594-601.

Mitchell, J.S. Johnson, D.C. Litchfield, K. Broderick, P. Weinhold, N. Davies, F.E. Gregory, W.A. Jackson, G.H. Kaiser, M. Morgan, G.J. others, (2015). Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Scientific reports, Vol.5.

Walker, B.A. Boyle, E.M. Wardell, C.P. Murison, A. Begum, D.B. Dahir, N.M. Proszek, P.Z. Johnson, D.C. Kaiser, M.F. Melchor, L. others, (2015). Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. Journal of clinical oncology, Vol.33, pp. 3911-3920.

Walker, B.A. Wardell, C.P. Melchor, L. Brioli, A. Johnson, D.C. Kaiser, M.F. Mirabella, F. Lopez-Corral, L. Humphray, S. Murray, L. Ross, M. Bentley, D. Gutiérrez, N.C. Garcia-Sanz, R. San Miguel, J. Davies, F.E. Gonzalez, D. Morgan, G.J. (2014). Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia, Vol.28 (2), pp. 384-390.  show abstract

Pawlyn, C. Kaiser, M.F. Davies, F.E. Morgan, G.J. (2014). Current and potential epigenetic targets in multiple myeloma. Epigenomics, Vol.6 (2), pp. 215-228.  show abstract

Pawlyn, C. Hookway, E. Cain, P. Pliuskys, L. Kaiser, M.F. Bright, M. Aronson, L.I. Murison, A. Lindow, M. Obad, S. Oerum, H. Opperman, U. Morgan, G.J. Davies, F.E. (2014). Histone Demethylase Inhibition As a Novel Therapeutic Strategy in Myeloma. Blood, Vol.124 (21).

Melchor, L. Brioli, A. Wardell, C.P. Murison, A. Potter, N.E. Kaiser, M.F. Fryer, R.A. Johnson, D.C. Begum, D.B. Hulkki Wilson, S. Vijayaraghavan, G. Titley, I. Cavo, M. Davies, F.E. Walker, B.A. Morgan, G.J. (2014). Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia, Vol.28 (8), pp. 1705-1715.  show abstract

Pawlyn, C. Khan, M.S. Muls, A. Sriskandarajah, P. Kaiser, M.F. Davies, F.E. Morgan, G.J. Andreyev, H.J. (2014). Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood, Vol.124 (15), pp. 2467-2468.

Brioli, A. Giles, H. Pawlyn, C. Campbell, J.P. Kaiser, M.F. Melchor, L. Jackson, G.H. Gregory, W.M. Owen, R.G. Child, J.A. Davies, F.E. Cavo, M. Drayson, M.T. Morgan, G.J. (2014). Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood, Vol.123 (22), pp. 3414-3419.  show abstract

Mirabella, F. Murison, A. Aronson, L.I. Wardell, C.P. Thompson, A.J. Hanrahan, S.J. Fok, J.H. Pawlyn, C. Kaiser, M.F. Walker, B.A. Davies, F.E. Morgan, G.J. (2014). A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. Plos one, Vol.9 (6), p. e99493.  show abstract

Mirabella, F. Wu, P. Wardell, C.P. Kaiser, M.F. Walker, B.A. Johnson, D.C. Morgan, G.J. (2013). MMSET is the key molecular target in t(4;14) myeloma. Blood cancer j, Vol.3 (5), p. e114.

Kaiser, M.F. Heider, U. Mieth, M. Zang, C. von Metzler, I. Sezer, O. (2013). The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. European journal of haematology, Vol.90 (4), pp. 263-272.

Brioli, A. Boyd, K.D. Kaiser, M.F. Pawlyn, C. Wu, P. Gregory, W.M. Owen, R. Ross, F.M. Jackson, G.H. Cavo, M. Davies, F.E. Morgan, G.J. (2013). Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. Br j haematol, Vol.161 (2), pp. 291-294.

Kaiser, M.F. Heider, U. Mieth, M. Zang, C. von Metzler, I. Sezer, O. (2013). The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling. Eur j haematol, Vol.90 (4), pp. 263-272.  show abstract

Kaiser, M.F. Walker, B.A. Hockley, S.L. Begum, D.B. Wardell, C.P. Gonzalez, D. Ross, F.M. Davies, F.E. Morgan, G.J. (2013). A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia, Vol.27 (8), pp. 1754-1757.

Wu, P. Agnelli, L. Walker, B.A. Todoerti, K. Lionetti, M. Johnson, D.C. Kaiser, M. Mirabella, F. Wardell, C. Gregory, W.M. Davies, F.E. Brewer, D. Neri, A. Morgan, G.J. (2013). Improved risk stratification in myeloma using a microRNA-based classifier. British journal of haematology, Vol.162 (3), pp. 348-359.

Brioli, A. Kaiser, M.F. Pawlyn, C. Wu, P. Gregory, W.M. Owen, R. Ross, F.M. Jackson, G.H. Cavo, M. Davies, F.E. Morgan, G.J. (2013). Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leuk lymphoma, Vol.54 (9), pp. 1975-1981.  show abstract

Kaiser, M.F. Johnson, D.C. Wu, P. Walker, B.A. Brioli, A. Mirabella, F. Wardell, C.P. Melchor, L. Davies, F.E. Morgan, G.J. (2013). Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood, Vol.122 (2), pp. 219-226.  show abstract

Walker, B.A. Wardell, C.P. Johnson, D.C. Kaiser, M.F. Begum, D.B. Dahir, N.B. Ross, F.M. Davies, F.E. Gonzalez, D. Morgan, G.J. (2013). Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood, Vol.121 (17), pp. 3413-3419.  show abstract

Lamottke, B. Kaiser, M. Mieth, M. Heider, U. Gao, Z. Nikolova, Z. Jensen, M.R. Sterz, J. von Metzler, I. Sezer, O. (2012). The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. Eur j haematol, Vol.88 (5), pp. 406-415.  show abstract

Morgan, G.J. Kaiser, M.F. (2012). How to use new biology to guide therapy in multiple myeloma. Hematology am soc hematol educ program, Vol.2012, pp. 342-349.  show abstract

Huetter, G. Kaiser, M. Neumann, M. Mossner, M. Nowak, D. Baldus, C.D. Goekbuget, N. Hoelzer, D. Thiel, E. Hofmann, W.-. (2011). Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia. Leukemia research, Vol.35 (5), pp. 614-619.

Kaiser, M. Kuehnl, A. Reins, J. Fischer, S. Ortiz-Tanchez, J. Schlee, C. Mochmann, L.H. Heesch, S. Benlasfer, O. Hofmann, W.-. Thiel, E. Baldus, C.D. (2011). Antileukemic activity of the HSP70 inhibitor pifithrin-mu in acute leukemia. Blood cancer journal, Vol.1.

Kühnl, A. Gökbuget, N. Kaiser, M. Schlee, C. Stroux, A. Burmeister, T. Mochmann, L.H. Hoelzer, D. Hofmann, W.-. Thiel, E. Baldus, C.D. (2011). Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. Blood, Vol.118 (24), pp. 6362-6367.  show abstract

Kühnl, A. Kaiser, M. Neumann, M. Fransecky, L. Heesch, S. Radmacher, M. Marcucci, G. Bloomfield, C.D. Hofmann, W.-. Thiel, E. Baldus, C.D. (2011). High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia. Leuk res, Vol.35 (12), pp. 1585-1590.  show abstract

Heider, U. Rademacher, J. Kaiser, M. Kleeberg, L. von Metzler, I. Sezer, O. (2010). Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin lymphoma myeloma leuk, Vol.10 (2), pp. 134-137.  show abstract

Kaiser, M. Lamottke, B. Mieth, M. Jensen, M.R. Quadt, C. Garcia-Echeverria, C. Atadja, P. Heider, U. von Metzler, I. Türkmen, S. Sezer, O. (2010). Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. Eur j haematol, Vol.84 (4), pp. 337-344.  show abstract

Sterz, J. Jakob, C. Kuckelkorn, U. Heider, U. Mieth, M. Kleeberg, L. Kaiser, M. Kloetzel, P.-. Sezer, O. von Metzler, I. (2010). BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma. Eur j haematol, Vol.85 (2), pp. 99-107.  show abstract

Heider, U. Kaiser, M. Mieth, M. Lamottke, B. Rademacher, J. Jakob, C. Braendle, E. Stover, D. Sezer, O. (2009). Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur j haematol, Vol.82 (1), pp. 31-38.  show abstract

von Metzler, I. Krebbel, H. Kuckelkorn, U. Heider, U. Jakob, C. Kaiser, M. Fleissner, C. Terpos, E. Sezer, O. (2009). Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase. J cancer res clin oncol, Vol.135 (2), pp. 173-179.  show abstract

von Metzler, I. Heider, U. Mieth, M. Lamottke, B. Kaiser, M. Jakob, C. Sezer, O. (2009). Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. Exp cell res, Vol.315 (14), pp. 2471-2478.  show abstract

Kleeberg, L. Morgera, S. Jakob, C. Hocher, B. Schneider, M. Peters, H. Rötzer, S. Müller, C. Kaiser, M. Fleissner, C. Heider, U. Neumayer, H.-. Sezer, O. (2009). Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy. Eur j med res, Vol.14 (2), pp. 47-54.  show abstract

Heider, U. von Metzler, I. Kaiser, M. Rosche, M. Sterz, J. Rötzer, S. Rademacher, J. Jakob, C. Fleissner, C. Kuckelkorn, U. Kloetzel, P.-. Sezer, O. (2008). Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur j haematol, Vol.80 (2), pp. 133-142.  show abstract

Kaiser, M. Mieth, M. Liebisch, P. Oberländer, R. Rademacher, J. Jakob, C. Kleeberg, L. Fleissner, C. Braendle, E. Peters, M. Stover, D. Sezer, O. Heider, U. (2008). Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur j haematol, Vol.80 (6), pp. 490-494.  show abstract

Jakob, C. Sterz, J. Liebisch, P. Mieth, M. Rademacher, J. Goerke, A. Heider, U. Fleissner, C. Kaiser, M. von Metzler, I. Müller, C. Sezer, O. (2008). Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia, Vol.22 (9), pp. 1767-1772.  show abstract

Hecht, M. von Metzler, I. Sack, K. Kaiser, M. Sezer, O. (2008). Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp cell res, Vol.314 (5), pp. 1082-1093.  show abstract

Schwarzer, R. Kaiser, M. Acikgoez, O. Heider, U. Mathas, S. Preissner, R. Sezer, O. Doerken, B. Jundt, F. (2008). Notch inhibition blocks multiple myeloma cell-induced osteoclast activation. Leukemia, Vol.22 (12), pp. 2273-2277.

Jakob, C. Egerer, K. Liebisch, P. Türkmen, S. Zavrski, I. Kuckelkorn, U. Heider, U. Kaiser, M. Fleissner, C. Sterz, J. Kleeberg, L. Feist, E. Burmester, G.-. Kloetzel, P.-. Sezer, O. (2007). Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood, Vol.109 (5), pp. 2100-2105.  show abstract

Hecht, M. Heider, U. Kaiser, M. von Metzler, I. Sterz, J. Sezer, O. (2007). Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br j haematol, Vol.138 (4), pp. 446-458.  show abstract

von Metzler, I. Krebbel, H. Hecht, M. Manz, R.A. Fleissner, C. Mieth, M. Kaiser, M. Jakob, C. Sterz, J. Kleeberg, L. Heider, U. Sezer, O. (2007). Bortezomib inhibits human osteoclastogenesis. Leukemia, Vol.21 (9), pp. 2025-2034.  show abstract

Zavrski, I. Jakob, C. Kaiser, M. Fleissner, C. Heider, U. Sezer, O. (2007). Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent results cancer res, Vol.176, pp. 165-176.  show abstract

Zavrski, I. Kleeberg, L. Kaiser, M. Fleissner, C. Heider, U. Sterz, J. Jakob, C. Sezer, O. (2007). Proteasome as an emerging therapeutic target in cancer. Curr pharm des, Vol.13 (5), pp. 471-485.  show abstract

Kaiser, M. Zavrski, I. Sterz, J. Jakob, C. Fleissner, C. Kloetzel, P.-. Sezer, O. Heider, U. (2006). The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, Vol.91 (2), pp. 248-251.

Heider, U. Kaiser, M. Sterz, J. Zavrski, I. Jakob, C. Fleissner, C. Eucker, J. Possinger, K. Sezer, O. (2006). Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur j haematol, Vol.76 (1), pp. 42-50.  show abstract

Kaiser, M. Zavrski, I. Sterz, J. Jakob, C. Fleissner, C. Kloetzel, P.-. Sezer, O. Heider, U. (2006). The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, Vol.91 (2), pp. 248-251.  show abstract

Jakob, C. Sterz, J. Zavrski, I. Heider, U. Kleeberg, L. Fleissner, C. Kaiser, M. Sezer, O. (2006). Angiogenesis in multiple myeloma. Eur j cancer, Vol.42 (11), pp. 1581-1590.  show abstract

Heider, U. Fleissner, C. Zavrski, I. Kaiser, M. Hecht, M. Jakob, C. Sezer, O. (2006). Bone markers in multiple myeloma. Eur j cancer, Vol.42 (11), pp. 1544-1553.  show abstract

Eucker, J. Sterz, J. Krebbel, H. Zavrski, I. Kaiser, M. Zang, C. Heider, U. Jakob, C. Elstner, E. Sezer, O. (2006). Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma. Anticancer drugs, Vol.17 (7), pp. 763-769.  show abstract

Heider, U. Kaiser, M. Müller, C. Jakob, C. Zavrski, I. Schulz, C.-. Fleissner, C. Hecht, M. Sezer, O. (2006). Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur j haematol, Vol.77 (3), pp. 233-238.  show abstract

Zavrski, I. Jakob, C. Schmid, P. Krebbel, H. Kaiser, M. Fleissner, C. Rosche, M. Possinger, K. Sezer, O. (2005). Proteasome: an emerging target for cancer therapy. Anticancer drugs, Vol.16 (5), pp. 475-481.  show abstract

Heider, U. Hofbauer, L.C. Zavrski, I. Kaiser, M. Jakob, C. Sezer, O. (2005). Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem biophys res commun, Vol.338 (2), pp. 687-693.  show abstract

Zavrski, I. Krebbel, H. Wildemann, B. Heider, U. Kaiser, M. Possinger, K. Sezer, O. (2005). Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem biophys res commun, Vol.333 (1), pp. 200-205.  show abstract

Weinhold, N. Johnson, D.C. Chubb, D. Broderick, P. Goldschmidt, H. Hemminki, K. Foersti, A. B, C. Hosking, F. Ma, Y. Davies, F. Gregory, W. Jackson, G. Witzens-Harig, M. Neben, K. Hoffmann, P. Nöthen, M. Mühleisen, T. Moebus, S. Ross, F. Jauch, A. Morgan, G. The CCND1 G870A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nature genetics, .  show abstract

Walker, B.A. Wardell, Brioli, A. Boyle, E. Kaiser, M.F. Begum, D.B. Dahir, N. Johnson, D.C. Ross, F.M. Davies, F.E. Morgan, G.J. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood csncer journal, Vol.14 (4), p. e191.  show abstract

Cerchione, C. Usmani, S.Z. Stewart, A.K. Kaiser, M. Rasche, L. Kortüm, M. Mateos, M.-. Spencer, A. Sonneveld, P. Anderson, K.C. Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. Frontiers in oncology, Vol.12.  show abstract

Sud, A. Went, M. Law, P. Kaiser, M. Houlston, R. The clinical utility of polygenic risk scores for multiple myeloma. European journal of human genetics, .

Kaiser, M. A double punch for plasma cell leukemia. Haematologica, Vol.108 (4), pp. 939-940.


Book Chapters

Kaiser, M.F. Boyd, K.D. Morgan, G.J. (2014). The genetic and epigenetic mechanisms underlying the behavior of myeloma. In Schey, S.A.Yong, K.L.Marcus, R.Anderson, K.C. (Eds.), MYELOMA: PATHOLOGY, DIAGNOSIS, AND TREATMENT. (pp. 48-16). CAMBRIDGE UNIV PRESS.

In this section

Publications Research Overview